Jonathan Riess

Title(s)Associate Professor, Hematology and Oncology
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemother Pharmacol. 2022 Jul 30. Chen JA, Huynh JC, Wu CY, Yu AM, Matsukuma K, Semrad TJ, Gandara DR, Li T, Riess JW, Tam K, Mack PC, Martinez A, Mahaffey N, Kelly KL, Kim EJ. PMID: 35907014.
      View in: PubMed   Mentions:    Fields:    
    2. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer. 2022 06; 10(6). Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. PMID: 35649657; PMCID: PMC9161072.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 05; 20(5):497-530. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. PMID: 35545176.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    4. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 2022 04; 166:107-113. Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroglu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. PMID: 35257949.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Transl Oncol. 2021 Oct; 14(10):101184. Riess JW, Rahman S, Kian W, Edgerly C, Heilmann AM, Madison R, Ramkissoon SH, Klaitman SS, Chung JH, Trabucco SE, Jin DX, Alexander BM, Klempner SJ, Albacker LA, Frampton GM, Roisman LC, Miller VA, Ross JS, Schrock AB, Gregg JP, Peled N, Sokol ES, Ali SM. PMID: 34333275; PMCID: PMC8340305.
      View in: PubMed   Mentions: 1  
    6. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 11; 22(6):601-606. Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. PMID: 34389237.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    7. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021 08; 88(2):335-341. Semrad TJ, Kim EJ, Gong IY, Li T, Christensen S, Arora M, Riess JW, Gandara DR, Kelly K. PMID: 33993383; PMCID: PMC8259450.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    8. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. Clin Lung Cancer. 2021 11; 22(6):e851-e855. Ji J, Mitra A, Camidge DR, Riess JW. PMID: 34059475.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021 07 20; 39(21):2339-2349. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. PMID: 33872070; PMCID: PMC8280089.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    11. Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model. Clin Lung Cancer. 2021 05; 22(3):153-155. Riess JW, Rolfo C, Gandara DR. PMID: 33879399.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precis Oncol. 2021; 5. Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. PMID: 34250387; PMCID: PMC8232122.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041. Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, Wakelee HA. PMID: 33588109.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    14. SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping. JTO Clin Res Rep. 2021 Apr; 2(4):100151. Lawrence MN, Tamen RM, Martinez P, Sable-Hunt A, Addario T, Barbour P, Shaffer T, Hosseini SA, Bertucci C, Lim LP, Hong F, Michael K, Simon GR, Riess JW, Awad MM, Oxnard GR. PMID: 34590008; PMCID: PMC8474207.
      View in: PubMed   Mentions:
    15. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220; PMCID: PMC8140807.
      View in: PubMed   Mentions: 3     Fields:    
    16. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clin Lung Cancer. 2021 01; 22(1):67-70. Riess JW, Frankel P, Shackelford D, Dunphy M, Badawi RD, Nardo L, Cherry SR, Lanza I, Reid J, Gonsalves WI, Kunos C, Gandara DR, Lara PN, Newman E, Paik PK. PMID: 33229301; PMCID: PMC7834952.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    17. Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. Curr Treat Options Oncol. 2020 06 25; 21(7):60. Chen JA, Riess JW. PMID: 32588244.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer. 2020 07 15; 126(14):3219-3228. Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR. PMID: 32365229; PMCID: PMC7383626.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    19. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2020 May; 12(5):2859-2876. Chen JA, Riess JW. PMID: 32642199; PMCID: PMC7330402.
      View in: PubMed   Mentions: 4  
    20. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. Am Soc Clin Oncol Educ Book. 2020 May; 40:372-384. Calles A, Riess JW, Brahmer JR. PMID: 32421452.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    21. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treat Res Commun. 2020 Apr 20; 23:100174. Riess JW, Jahchan NS, Das M, Zach Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. PMID: 32413603; PMCID: PMC7572629.
      View in: PubMed   Mentions: 4     Fields:    
    22. Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors. Lung Cancer (Auckl). 2020; 11:33-39. Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM. PMID: 32368168; PMCID: PMC7184117.
      View in: PubMed   Mentions: 1  
    23. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Rev Anticancer Ther. 2019 12; 19(12):1061-1075. Blakely CM, Riess JW. PMID: 31809604.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    24. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 2019 11; 137:71-75. Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro-Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ. PMID: 31557562.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    25. MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. Oncologist. 2019 10; 24(10):1305-1308. Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW. PMID: 31391294; PMCID: PMC6795166.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842. Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. PMID: 31300450; PMCID: PMC6774853.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    27. A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry. Clin Lung Cancer. 2019 11; 20(6):477-483. Benjamin DJ, Klapheke A, Lara PN, Cress RD, Riess JW. PMID: 31375453; PMCID: PMC7179575.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clin Lung Cancer. 2019 07; 20(4):e489-e491. Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW. PMID: 31085042.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clin Lung Cancer. 2019 05; 20(3):e407-e412. Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW. PMID: 30808583.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    30. EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. Clin Lung Cancer. 2019 05; 20(3):e238-e241. Narayanan A, Knollmann FD, Walby JAS, Lim S, Gandara DR, Riess JW. PMID: 30679078.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    31. Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clin Lung Cancer. 2019 05; 20(3):e356-e361. Riess JW, Kong CS, West RB, Padda SK, Neal JW, Wakelee HA, Le QT. PMID: 30773448.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    32. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res. 2019 02 01; 79(3):546-556. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. PMID: 30538120; PMCID: PMC6359944.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    33. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS One. 2018; 13(11):e0208097. Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA. PMID: 30481207; PMCID: PMC6258560.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 09 01; 4(9):1197-1198. Gandara DR, Riess JW, Lara PN. PMID: 29902311.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018 10; 13(10):1560-1568. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. PMID: 29981927; PMCID: PMC6764748.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    36. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res. 2018 12 01; 24(23):5841-5849. Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA. PMID: 29891725.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    37. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. PMID: 29885479.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    38. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018 07 01; 36(19):1905-1912. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. PMID: 29746230; PMCID: PMC6553840.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    39. Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. J Thorac Imaging. 2018 May; 33(3):176-183. Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA. PMID: 29219888; PMCID: PMC6368176.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    40. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 05 10; 36(14):1412-1418. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. PMID: 29584545; PMCID: PMC5941615.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCTClinical Trials
    41. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist. 2018 07; 23(7):764-e86. Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Colevas AD. PMID: 29540603; PMCID: PMC6058339.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    42. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 05; 17(5):885-896. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. PMID: 29483211; PMCID: PMC5932243.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    43. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol. 2018 03; 13(3):436-446. Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS. PMID: 29191778; PMCID: PMC5983900.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    44. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCells
    45. Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):647-651. Hegde JV, Shaverdian N, Felix C, Wang PC, Veruttipong D, Hsu S, Riess JW, Rao SD, Daly ME, Chen AM. PMID: 29246721.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    46. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer. 2018 02 01; 124(3):521-529. Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM. PMID: 29044458; PMCID: PMC5916816.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    47. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 10; 112:165-168. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. PMID: 29191590.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. PMID: 28447912; PMCID: PMC5559893.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    49. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 11 01; 34(31):3717-3718. Riess JW, Lara PN, Gandara DR. PMID: 27601544; PMCID: PMC5477925.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol. 2016 Mar; 28(2):97-103. Parikh M, Riess J, Lara PN. PMID: 26844984; PMCID: PMC5139911.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    52. Multidisciplinary Care. Cancer Treat Res. 2016; 170:285-300. Daly ME, Riess JW. PMID: 27535399.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Pruritus as a Paraneoplastic Symptom of Thymoma. J Thorac Oncol. 2015 Nov; 10(11):e110-2. Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ, Loo BW, Neal JW, Hardy R, Wakelee HA. PMID: 26536199; PMCID: PMC4720251.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689; PMCID: PMC4734742.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    55. Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer. 2015 Sep; 89(3):280-6. Das M, Padda SK, Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelee HA. PMID: 26149476; PMCID: PMC4613811.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    56. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158; PMCID: PMC4586173.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    57. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015 Mar; 10(3):500-8. Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. PMID: 25402569; PMCID: PMC4720257.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    58. GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Res. 2015 Feb; 35(2):669-76. Riess JW, West R, Dean M, Klimowicz AC, Neal JW, Hoang C, Wakelee HA. PMID: 25667444; PMCID: PMC5973531.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer. 2015 Jan; 87(1):34-8. Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. PMID: 25443273.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    60. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol. 2014 Apr; 36(2):182-6. Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. PMID: 24494587; PMCID: PMC6464638.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):93-5. Riess JW, Lara PN. PMID: 24529447; PMCID: PMC4184801.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    62. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014 May; 15(3):202-6. Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA. PMID: 24524822; PMCID: PMC6314305.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    63. Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape. Am J Manag Care. 2013 Dec; 19(19 Suppl):s390-7. Riessk J. PMID: 24494720.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    64. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014 Feb 04; 110(3):602-8. Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. PMID: 24292447; PMCID: PMC3915116.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    65. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733; PMCID: PMC4586161.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    66. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013 Oct; 5 Suppl 5:S556-64. Lwin Z, Riess JW, Gandara D. PMID: 24163748; PMCID: PMC3804876.
      View in: PubMed   Mentions: 14  
    67. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 2013 Dec; 3(12):1364-77. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J. PMID: 24078773; PMCID: PMC3864571.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCells
    68. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. PMID: 24013936; PMCID: PMC4562389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    69. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer. 2013 Sep; 14(5):592-5. Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA. PMID: 23810364; PMCID: PMC4156821.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    70. A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):389-94. Riess JW, Nagpal S, Neal JW, Wakelee HA. PMID: 23584342; PMCID: PMC6329611.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013 Feb; 8(2):e17-8. Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. PMID: 23328555; PMCID: PMC3552378.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S385-6. Riess JW, Neal JW. PMID: 23160327.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Treatment of leptomeningeal spread of NSCLC: a continuing challenge. Curr Treat Options Oncol. 2012 Dec; 13(4):491-504. Nagpal S, Riess J, Wakelee H. PMID: 22836285.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    74. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer. 2012 Aug; 77(2):421-6. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH. PMID: 22555222.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    75. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clin Adv Hematol Oncol. 2012 Apr; 10(4):226-34. Riess JW, Wakelee HA. PMID: 22706483.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    76. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012 Mar; 30(3):231-5. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. PMID: 22360362.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    77. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1797-8. Riess JW, Neal JW. PMID: 22005534.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002 Jul; 8(7):681-6. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. PMID: 12042777.
      View in: PubMed   Mentions: 244     Fields:    Translation:HumansCells
    Jonathan's Networks
    Concepts (266)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (55)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB01.

    Copyright © The Regents of the University of California